Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal

Published Date: 08 Aug 2026

The planned label change follows failure of lurbinectedin to improve overall survival in the phase 3 postmarketing trial; the first-line maintenance indication remains unaffected.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Early Tislelizumab May Boost PFS in Esophageal Cancer

2.

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

3.

Woman Loses 6-Year Battle With Mouth Tumor

4.

Early Sugar Exposure and Cancer Risk; Melanoma Vaccine Win; 'Antifreeze' for CAR-T

5.

The biology of cancer as well as potential treatment options are examined by experts.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot